HAtV CP Specific Neutra™ Antibody Products

Are you currently facing challenges such as low neutralization potency in astrovirus assays, difficulty in identifying conserved epitopes across serotypes, or complex viral entry mechanisms that hinder drug development? Our HAtV CP Specific Neutra™ Antibody Products help you accelerate vaccine development and obtain high-quality neutralizing data through our advanced B-cell sorting and phage display platforms, specifically targeting the critical spike domain of the Human Astrovirus Capsid Protein (CP).

Introduction of HAtV CP

Human Astrovirus (HAstV) is a major etiological agent of acute gastroenteritis, particularly in children, the elderly, and immunocompromised populations. The virus is non-enveloped, featuring a T=3 icosahedral capsid that protects its positive-sense, single-stranded RNA genome.

Structure and Maturation

The HAtV capsid protein (CP) is initially synthesized as a ~90 kDa precursor (VP90). It undergoes a sophisticated maturation process involving proteolytic cleavage by both cellular caspases and extracellular proteases like trypsin. This processing removes the acidic C-terminal domain and breaks down the CP into three main fragments: VP34 (core), VP27/29, and VP25/26 (spike).

Function and Pathogenesis

The CP is the primary determinant of HAtV infectivity. The spike domain (P2 domain) acts as the receptor-binding domain (RBD), facilitating attachment to host cell receptors (such as FcRn) and triggering clathrin-dependent endocytosis. Beyond entry, the CP modulates host immune responses by interacting with complement proteins like C1q, potentially inhibiting the classical complement pathway to evade host defenses.

Fig.1 Replication cycle of human astroviruses.¹

Signaling Modulation

A key feature of the HAstV capsid is its ability to act as a complement inhibitor; specifically, it binds to C1q, inhibiting the activation of the classical complement pathway and reducing inflammatory responses. Additionally, during the viral life cycle, the capsid protein is known to induce apoptosis via the caspase-activation pathway, which facilitates efficient viral progeny release. Emerging evidence also suggests that HAstV components can interfere with the RIG-I-like receptor signaling pathway, suppressing the induction of Type I Interferons to evade the host's initial antiviral defenses.

Clinical Impact

HAtV infections typically manifest as watery diarrhea, vomiting, and fever. While often self-limiting in healthy adults, chronic and systemic infections, including those affecting the central nervous system (encephalitis), have been documented in severely immunocompromised patients. The lack of approved vaccines or antivirals underscores the urgent need for high-quality neutralizing antibodies for both research and passive immunotherapy development.

Applications of Anti HAtV CP Neutralizing Antibodies

Neutralizing antibodies against the HAtV CP are indispensable tools across multiple scientific disciplines:

• Vaccine Development: They serve as gold-standard controls in neutralization assays (FRNT/PRNT) to evaluate the immunogenicity of VLP-based or recombinant vaccine candidates.
• Therapeutic Research: In immunocompromised patients where persistent HAstV infection occurs, these antibodies are being explored for passive immunotherapy to reduce viral load and accelerate recovery.
• Diagnostic Innovation: Anti-CP antibodies are used in high-sensitivity sandwich ELISAs and lateral flow assays to detect active viral shedding in clinical samples.
• Mechanistic Studies: Researchers utilize neutralizing fragments (scFv, Fab) to study the conformational changes induced by trypsin maturation and to identify the still-elusive host cell receptors.

Our Anti-HAtV CP Neutralizing Antibodies

Creative Biolabs provides a comprehensive portfolio of HAtV CP specific antibodies tailored for high-end research needs. Our Neutra™ line includes:

• Recombinant Monoclonal Antibodies: Full-length IgG (Mouse, Human, or Chimeric) with validated neutralization profiles against major HAstV serotypes (HAstV-1 to HAstV-8).
• Antibody Fragments: scFv and Fab fragments (including the PL-2 equivalent) optimized for structural biology and co-crystallization studies.
• Pan-Serotype Neutralizers: Engineered antibodies targeting conserved residues within the spike domain to provide broader protection across divergent astrovirus strains.
• Custom Conjugations: Antibodies pre-conjugated with biotin, HRP, or fluorophores for specialized imaging and detection workflows.

All our products undergo rigorous QC, including SPR affinity measurement and virus neutralization testing, to ensure they meet the highest scientific standards.

Creative Biolabs is dedicated to providing the global scientific community with superior HAtV CP Specific Neutra™ Antibody Products. Whether you are navigating early-stage drug discovery or validating a novel vaccine platform, our expertise in astrovirus immunology ensures you have the most effective tools at your disposal. For detailed technical specifications, custom antibody engineering services, or bulk ordering information, please reach out to our specialist team.

Reference

1. Arias, Carlos F, and Rebecca M DuBois. "The Astrovirus Capsid: A Review." Viruses vol. 9,1 15. 19 Jan. 2017, Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v9010015